Inari Medical announced the first patient enrollment in the PEERLESS II study. This prospective, global, multi-center randomized controlled trial, or RCT, compares the outcomes of intermediate-risk acute pulmonary embolism, or PE, patients treated with the FlowTriever System against those treated with traditional anticoagulation therapy alone.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NARI:
- Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)
- Inari Medical management to meet with Piper Sandler
- Inari Medical Closes Acquisition of LimFlow
- Inari Medical to Present at Upcoming Investor Conferences
- Inari Medical price target lowered to $68 from $84 at Canaccord
